NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/19/2025
Back to search
Official data from USPTO
MABQI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MABQI
ST13
US500000079322137Class
1, 5, 40, 42, 44, 45
Filing
79322137
Registration
6886608
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/20/2025
Trademark type
Word
Nice classes
1, 5, 40, 42, 44, 45
Filing date
06/11/2021
Registration date
11/01/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/01/2022
Last transaction
06/20/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
FR
Examiner
CHHINA, KARAN
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
MABQI
Representatives
Ronald M. Kachmarik Cooper Legal Group, LLC
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical products for use in industry and science; chemical preparations for scientific useother than for medical or veterinary use; biological preparations for use in industry and science; chemical reagents other than for medical or veterinary use; chemical products for analyses in laboratories other than for medical or veterinary use; diagnostic preparations other than for medical or veterinary use; biological preparations other than for medical or veterinary use; monoclonal antibodies for scientific use; all these goods exclusively in the field of antibody generation
Class 5
Pharmaceutical products for treatment of metabolic diseasesgastroenterological diseasesinflammatory diseasesauto-immune diseasescancer diseasesneurological diseases and infectious diseases; chemical preparations for medical or pharmaceutical use for treating metabolic diseasesgastroenterological diseasesinflammatory diseasesauto-immune diseasescancer diseasesneurological diseases and infectious diseases; medical diagnostic preparations; chemical reagents for medical or veterinary use; all these goods exclusively in the field of antibody generation
Class 40
Custom manufacturing of pharmaceutical products for third parties; these services exclusively in the field of antibody generation
Class 42
Research laboratory services; biological research; scientific research; clinical research; biochemical research; biotechnological research services; medical research; research in the field of pharmaceutical products; research and development of new products for third parties; technical research; engineering; technical scientific project study; research scientific project study; all these services exclusively in the field of antibody generation
Class 44
Advisory services and information services relating to diagnostic and therapeutic properties in the field of pharmaceuticals; information and advisory services in the medical field; medical services; all these services exclusively in the field of antibody generation
Class 45
Intellectual property licensing; licensing of patents; legal servicescopyright and industrial property right licensing; all these services exclusively in the field of antibody generation
Publications
History of USPTO decisions and trademark events.
26 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/21/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/23/2023
FIMP
FINAL DISPOSITION PROCESSED
02/23/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/01/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2022
GPNX
NOTIFICATION PROCESSED BY IB
08/16/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2022
PUBO
PUBLISHED FOR OPPOSITION
08/16/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/27/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/06/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/06/2022
RFNT
REFUSAL PROCESSED BY IB
06/06/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/16/2022
RFRR
REFUSAL PROCESSED BY MPU
05/16/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/01/2022
CNRT
NON-FINAL ACTION WRITTEN
03/31/2022
DOCK
ASSIGNED TO EXAMINER
03/02/2022
MAFR
APPLICATION FILING RECEIPT MAILED
10/16/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/08/2021
Continuous trademark protection
Get notified about every new filing that threatens MABQI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.